Workflow
精密机械零部件
icon
Search documents
私募基金入股联诚精密1.5亿“扫货”6.71%股份
Xin Lang Cai Jing· 2026-01-12 03:04
转自:经济导报 文 | 经济导报 贾义航 值得一提的是,联诚精密已向国内工业机器人头部企业批量供应相关零件产品,与珞石机器人有限公司 等建立了业务关系。联诚重机事业部也已成为河北智昆精密传动科技有限责任公司的行星架核心供应 商,为其供应行星减速机核心部件。 业绩方面,2024年联诚精密实现营业收入10.75亿元,同比下降2.62%;归母净利润-3795.74万元,同比 大跌878.93%。2025年前三季度,公司实现营业收入8.56亿元,同比增长5.53%;归母净利润-1148.47万 元,同比减亏53.05%。 二级市场上,1月7日,联诚精密收盘价为17.13元/股。1月8日,公司股价上涨,截至收盘上涨5.78%, 报收18.12元/股,全天换手率13.15%,成交量16.9万手。 翠丽控股系联诚精密控股股东、实际控制人郭元强的一致行动人。本次协议转让前,郭元强及翠丽控股 合计持有公司3600万股,占公司总股本的24.16%;本次协议转让后,郭元强及翠丽控股合计持有公司 3400万股,占公司总股本的22.82%。因此,本次交易不触及要约收购,不会导致公司控股股东、实际 控制人发生变化,不会对公司治理结构及持 ...
江顺科技大涨7.25%,成交额1.17亿元,主力资金净流出450.14万元
Xin Lang Cai Jing· 2026-01-08 02:03
1月8日,江顺科技盘中上涨7.25%,截至09:35,报100.68元/股,成交1.17亿元,换手率7.90%,总市值 60.41亿元。 资金流向方面,主力资金净流出450.14万元,特大单买入200.90万元,占比1.72%,卖出696.65万元,占 比5.98%;大单买入1045.59万元,占比8.97%,卖出999.98万元,占比8.58%。 江顺科技今年以来股价涨29.48%,近5个交易日涨35.07%,近20日涨50.49%,近60日涨55.97%。 分红方面,江顺科技A股上市后累计派现4800.00万元。 机构持仓方面,截止2025年9月30日,江顺科技十大流通股东中,兴全合远两年持有混合A(011338) 位居第六大流通股东,持股20.78万股,为新进股东。 责任编辑:小浪快报 资料显示,江苏江顺精密科技集团股份有限公司位于江苏省江阴市周庄镇玉门西路19号,成立日期2001 年10月19日,上市日期2025年4月24日,公司主营业务涉及铝型材挤压模具及配件、铝型材挤压配套设 备、精密机械零部件等产品的研发、设计、生产和销售。主营业务收入构成为:铝型材挤压模具及配件 41.78%,铝型材挤压配套设 ...
江顺科技股价涨5.07%,兴证全球基金旗下1只基金位居十大流通股东,持有20.78万股浮盈赚取81.67万元
Xin Lang Cai Jing· 2026-01-06 02:03
兴全合远两年持有混合A(011338)成立日期2021年4月27日,最新规模18.68亿。今年以来收益 3.04%,同类排名1404/8816;近一年收益53.83%,同类排名1560/8081;成立以来收益6.28%。 兴全合远两年持有混合A(011338)基金经理为吴钊华。 1月6日,江顺科技涨5.07%,截至发稿,报81.51元/股,成交7017.43万元,换手率5.85%,总市值48.91 亿元。 资料显示,江苏江顺精密科技集团股份有限公司位于江苏省江阴市周庄镇玉门西路19号,成立日期2001 年10月19日,上市日期2025年4月24日,公司主营业务涉及铝型材挤压模具及配件、铝型材挤压配套设 备、精密机械零部件等产品的研发、设计、生产和销售。主营业务收入构成为:铝型材挤压模具及配件 41.78%,铝型材挤压配套设备37.87%,精密机械零部件15.03%,其他业务5.31%。 从江顺科技十大流通股东角度 数据显示,兴证全球基金旗下1只基金位居江顺科技十大流通股东。兴全合远两年持有混合A (011338)三季度新进十大流通股东,持有股数20.78万股,占流通股的比例为1.39%。根据测算,今日 浮盈赚 ...
江顺科技1月5日获融资买入3804.07万元,融资余额1.34亿元
Xin Lang Cai Jing· 2026-01-06 01:45
1月5日,江顺科技跌0.23%,成交额2.81亿元。两融数据显示,当日江顺科技获融资买入额3804.07万 元,融资偿还3207.00万元,融资净买入597.07万元。截至1月5日,江顺科技融资融券余额合计1.35亿 元。 融资方面,江顺科技当日融资买入3804.07万元。当前融资余额1.34亿元,占流通市值的11.56%。 机构持仓方面,截止2025年9月30日,江顺科技十大流通股东中,兴全合远两年持有混合A(011338) 位居第六大流通股东,持股20.78万股,为新进股东。 责任编辑:小浪快报 资料显示,江苏江顺精密科技集团股份有限公司位于江苏省江阴市周庄镇玉门西路19号,成立日期2001 年10月19日,上市日期2025年4月24日,公司主营业务涉及铝型材挤压模具及配件、铝型材挤压配套设 备、精密机械零部件等产品的研发、设计、生产和销售。主营业务收入构成为:铝型材挤压模具及配件 41.78%,铝型材挤压配套设备37.87%,精密机械零部件15.03%,其他业务5.31%。 截至9月30日,江顺科技股东户数6896.00,较上期减少5.12%;人均流通股2175股,较上期增加5.39%。 2025年1月 ...
江顺科技12月18日获融资买入1365.81万元,融资余额1.11亿元
Xin Lang Cai Jing· 2025-12-19 01:34
12月18日,江顺科技跌1.97%,成交额8876.57万元。两融数据显示,当日江顺科技获融资买入额 1365.81万元,融资偿还906.23万元,融资净买入459.58万元。截至12月18日,江顺科技融资融券余额合 计1.11亿元。 融资方面,江顺科技当日融资买入1365.81万元。当前融资余额1.11亿元,占流通市值的11.13%。 机构持仓方面,截止2025年9月30日,江顺科技十大流通股东中,兴全合远两年持有混合A(011338) 位居第六大流通股东,持股20.78万股,为新进股东。 责任编辑:小浪快报 截至9月30日,江顺科技股东户数6896.00,较上期减少5.12%;人均流通股2175股,较上期增加5.39%。 2025年1月-9月,江顺科技实现营业收入7.13亿元,同比减少13.68%;归母净利润6545.07万元,同比减 少40.15%。 分红方面,江顺科技A股上市后累计派现4800.00万元。 融券方面,江顺科技12月18日融券偿还0.00股,融券卖出1800.00股,按当日收盘价计算,卖出金额 11.92万元;融券余量2900.00股,融券余额19.20万元。 资料显示,江苏江顺精密科技 ...
联诚精密:公司主要从事各种精密机械零部件的研发设计、生产和销售
Zheng Quan Ri Bao Wang· 2025-12-12 12:46
证券日报网讯12月12日,联诚精密(002921)在互动平台回答投资者提问时表示,公司主要从事各种精 密机械零部件的研发设计、生产和销售,公司产品广泛应用于商用空调压缩机、工业机器人、工程机 械、商用车、乘用车、液压机械、农业机械等多种行业。公司已向国内工业机器人头部企业批量供应相 关零件产品,公司一直致力于新客户及新业务的拓展,新产品的开发,未来如有对公司经营业绩有重大 影响的事项,公司将按照有关法律法规的要求及时进行信息披露。 ...
北交所 2025 年 11 月月报:北证 50 震荡走低,北交所新股创首日涨幅记录-20251204
Guoxin Securities· 2025-12-04 07:41
Investment Rating - The report maintains an "Outperform" rating for the industry [5] Core Insights - The North Exchange 50 index experienced a significant decline of 12.32% in November 2025, with the index closing at 1,387.70 points [31] - The total number of listed companies on the North Exchange reached 285, with a total market capitalization of 827.155 billion and a circulating market value of 507.712 billion, reflecting a decrease of 10.2% and 11.2% respectively [11][18] - The report highlights that all sectors within the North Exchange experienced declines, with the most significant drops in household appliances, transportation, communication, automotive, and non-ferrous metals [35] Market Overview - The trading volume for November was 16.987 billion shares, with a total transaction value of 376.778 billion, marking a month-on-month increase of 9.9% in volume and 3.1% in value [18][21] - The average daily margin balance for the North Exchange in November was 7.789 billion, showing a month-on-month increase of 2.35% [22] Valuation Metrics - As of November 28, the North Exchange 50 index had a price-to-earnings ratio (PE-TTM) of 43.07, placing it at the 67.98th percentile over the past two years, while the price-to-book ratio (PB-MRQ) was 8.89, at the 75.21st percentile [24][27] - The dividend yield was reported at 0.78, corresponding to the 26.56th percentile over the same period [24] Industry Performance - The report indicates that the North Exchange's specialized and innovative index fell by 13.44% in November, with other major indices also experiencing declines, including the Sci-Tech 50 down 6.24% and the ChiNext index down 4.23% [31] - The report notes that the North Exchange's new listings included five companies: Danna Biological, Zhongcheng Consulting, Beikang Testing, Dapeng Industrial, and Nante Technology [11][3] Policy and Events - In November 2025, the Beijing Stock Exchange introduced a series of policies aimed at enhancing market vitality and solidifying institutional foundations, achieving progress in information disclosure, institutional behavior, new stock performance, and ongoing supervision [4]
IPO要闻汇 | 本周2只新股申购,族兴新材等3家公司将上会
Cai Jing Wang· 2025-12-01 10:14
IPO Review and Registration Progress - Three companies were reviewed for IPO, with two approvals and one deferral. Yongda Co. faced a deferral, while Meidele and Haifiman received approvals [2][3] - Yongda Co. reported a revenue of 361 million yuan for the first three quarters of 2025, a year-on-year decline of 25.16%, and a net profit of 70 million yuan, down 3.34% [2] - Meidele's revenue from products used in the new energy battery sector accounted for about 60% of its main business income, with a high customer concentration [2] - Haifiman specializes in high-end audio products, facing inquiries regarding its technological advancements and acquisition rationality [3] Upcoming IPOs - Three companies are set to present for IPO this week: Zuxing New Materials, Mirui Technology, and Jintai Co., all targeting the Beijing Stock Exchange [4] - Zuxing New Materials has previously attempted IPOs in 2016 and 2020 but withdrew applications. Its revenue for 2022 to 2024 was 629 million, 690 million, and 707 million yuan, with net profits showing fluctuations [4][5] - Mirui Technology's revenue for the first three quarters of 2025 was 549 million yuan, down 0.95%, with a net profit of 51 million yuan, down 12.93% [6] New Stock Listings - Two new stocks were listed last week: Hai'an Group and Nante Technology, with Nante's first-day increase of 183.03% [13][14] - This week, Jingchuang Electric is scheduled to list, with an issue price of 12.1 yuan per share. For the first three quarters of 2025, it reported a revenue of 403 million yuan, up 9.48% [13] Recent IPO Approvals and Terminations - Two IPO registrations were approved: Zhixin Co. and Qiangyi Co. [10] - Zhixin Co. plans to raise 1.329 billion yuan for production line expansion and working capital, while Qiangyi Co. focuses on semiconductor testing hardware [11] - Two IPO applications were terminated due to voluntary withdrawals, including Mingshan Environmental Energy [12] Upcoming New Stock Subscriptions - Two new stocks are set for subscription this week: Muxi Co. and Angrui Micro, both targeting the Sci-Tech Innovation Board [15] - Muxi Co. aims to raise 3.904 billion yuan for GPU development projects, reporting a revenue of 1.236 billion yuan for the first three quarters of 2025, up 453.52% [15] - Angrui Micro plans to raise 2.067 billion yuan for 5G chip development, with a revenue of 1.335 billion yuan and a net loss of 63 million yuan for the same period [16]
2家过会1家暂缓丨IPO一周要闻
Sou Hu Cai Jing· 2025-11-30 00:12
Group 1: IPO Review and Approval - This week, the Beijing Stock Exchange (BSE) concluded its IPO review, with 3 companies undergoing scrutiny and 2 successfully passing the review [2] - Yongda Co., Ltd. became the first project this year to have its IPO review postponed, raising market concerns due to ongoing issues regarding the sustainability of its performance and the rationality of its fundraising projects [2] - Yongda has adjusted its fundraising plans twice during the review process, eliminating a liquidity support project and reducing the proposed investment scale for its "Heavy Chemical Equipment Production Base Phase I" project, adding uncertainty to its review [2] Group 2: Companies Approved for IPO - Kunshan Haifiman Technology Group Co., Ltd. was approved for IPO, specializing in high-end audio products under the brand "HIFIMAN," with projected revenues of 1.54 billion yuan in 2022 and a net profit of 360 million yuan [3] - Dalian Meidele Industrial Automation Co., Ltd. also received approval, focusing on intelligent manufacturing equipment, with revenues of 10.31 billion yuan in 2022 and a net profit of 2.22 billion yuan [4] Group 3: Newly Listed Companies - Hai'an Group officially listed on the Shenzhen Stock Exchange, opening with a surge of over 68%, closing at 83.52 yuan per share, with a total market value of 15.532 billion yuan [5] - Innovation Industry, an electrolytic aluminum company, debuted on the Hong Kong Stock Exchange with a first-day increase of 32.76%, focusing on alumina refining and electrolytic aluminum smelting [6] - Nant Technology saw a significant first-day increase of 183.03% on the BSE, closing at 24.51 yuan per share [7] Group 4: Companies Filing for IPO - Kewang Pharmaceutical, founded in 2017, focuses on tumor immunotherapy with a pipeline of 7 major assets, including the core product ES102, which is in clinical development [11] - Mingyu Pharmaceutical, established in 2018, has a core pipeline in the tumor field, including ADC and dual-target antibodies, with a recent valuation of 3.936 billion yuan after a financing round [12] - Baoji Pharmaceutical, founded in 2019, specializes in recombinant biopharmaceuticals and is in the clinical stage with its core pipeline KJ017, aimed at treating complex diseases [13]
南特科技上市首日融资余额1058.93万元
Core Points - Nant Technology (920124) experienced a significant increase of 183.03% on its first trading day, with a turnover rate of 68.63% and a transaction volume of 1.396 billion yuan [2] - The stock's first-day margin trading saw a buy amount of 11.6866 million yuan, accounting for 0.84% of the total trading volume, while the latest margin balance stood at 10.5893 million yuan, representing 0.56% of the circulating market value [2] Company Overview - Nant Technology specializes in the research, development, production, and sales of precision mechanical components [3] Recent IPO Performance - The first-day performance of Nant Technology is part of a broader trend observed in recent IPOs, with various companies showing notable first-day price increases and margin trading activities [3][4] - The table of recent IPOs indicates that Nant Technology's first-day increase of 183.03% is among the highest, with other companies like C Hai'an (74.00%) and Dapeng Industry (1211.11%) also showing significant gains [3][4]